Nacuity Pharmaceuticals, Inc.
5 clinical trials · Sponsor
◉ Watch Nacuity Pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome (NCT07290530) | Nacuity Pharmaceuticals, Inc. | 2026-12-01 |
| A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome (NCT07710196) | Nacuity Pharmaceuticals, Inc. | 2026-08-01 |
| PK and PD Study of NPI-001 and Cysteamine Bitartrate (NCT05994534) | Nacuity Pharmaceuticals, Inc. | 2023-10-29 |
| NPI-002 Intravitreal Implant for the Delay of Cataract Progression (NCT05026632) | Nacuity Pharmaceuticals, Inc. | 2022-01-27 |
| Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome (NCT04355689) | Nacuity Pharmaceuticals, Inc. | 2020-09-03 |
Track Nacuity Pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.